MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/1756-185x.14742

Медицинская библиотека · International journal of rheumatic diseases · 2023

Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitor golimumab: Results of a 24-Month prospective observation study (GO-COX Study).

Erdes Shandor, Agafonova Ekaterina M, Timokhina Daria G, Davidian Satenik Y, Zemerova Elena V, Kulikov Aleksey I, Markova Olga G, Achikyan Vladimir F

СтатьяПеревод в очереди

Аннотация

AIM: The hip joint is the most commonly affected non-axial joint in ankylosing spondylitis (AS). Data on the effects of tumor necrosis factor-α inhibitors (TNFi) in AS patients with coxitis are limited. The aim of this study was evaluation of coxitis treated with the TNFi golimumab in real-world settings.

METHODS

This study was a prospective non-interventional cohort study. A total of 39 patients newly prescribed with golimumab were enrolled and followed for up to 24 months. The data collected included BASFI, BASMI, ASDAS-CRP, BASDAI indices. BASRI-hip X-ray score was assessed at baseline, and at 12 and 24 months. Magnetic resonance imaging (MRI) and ultrasound examination data were obtained at baseline, and at 6 and 12 months.

RESULTS

Significant improvements in BASFI, BASMI, ASDAS-CRP, BASDAI scores were observed (P ≤ 0.0001), but the BASRI-hip score remained stable. After 6 months of treatment, MRI signs of joint effusion were found in a smaller percentage of patients compared with baseline (P = 0.005 for the right and P = 0.015 for the left hip joints). After 12 months, this percentage was significantly lower than at baseline for the right hip joint (P = 0.005) and numerically lower for the left hip joint (P = 0.098). Ultrasound showed a significant increase in the percentage of patients without inflammatory changes after 6 and 12 months compared with baseline (right hip joint: P = 0.026 and P = 0.045, respectively; left hip joint: P = 0.026 for both time points).

CONCLUSION

Golimumab therapy in AS patients with coxitis was accompanied by improvement in clinical scores, and in MRI and ultrasound findings without obvious radiographic progress.

Для цитирования: Erdes Shandor, Agafonova Ekaterina M, Timokhina Daria G, Davidian Satenik Y, Zemerova Elena V, Kulikov Aleksey I, Markova Olga G, Achikyan Vladimir F. Improvement of clinical and radiological manifestations of coxitis in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitor golimumab: Results of a 24-Month prospective observation study (GO-COX Study).. International journal of rheumatic diseases. 2023. DOI: 10.1111/1756-185x.14742.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.